The Role of CD8+ cells in the Development of Oral Tolerance
The Role of CD8+ cells in the Development of Oral Tolerance
批准号:
7882341
负责人:
Paul Michael Arnaboldi
金额:
$5.38万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2011-06-30
关键词:
AddressAffinityAnimal ModelAntibodiesAntigensAutoimmune DiseasesBindingBiological AssayBiological ModelsBolus InfusionC57BL/6 MouseCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCell ProliferationCell physiologyCellsClinical TrialsDataDefectDevelopmentDiseaseDoseFailureFlow CytometryGenerationsHistocompatibility Antigens Class IHumanImmuneImmune responseImmune systemImmunizationIn VitroInflammatory Bowel DiseasesIngestionIntestinal MucosaKnockout MiceLabelMHC Class I GenesMediatingMediator of activation proteinModelingMorphologic artifactsMusOralOral AdministrationPatientsPeptide/MHC ComplexPeptidesPlayPopulationProductionProteinsRegulatory T-LymphocyteRelative (related person)RoleSiteSpecificityStaining methodStainsT-LymphocyteTestingTherapeuticTransgenic MiceTreatment ProtocolsTweensVariantcell typecytokinefeedinghuman diseasenoveloral toleranceresponsesuccessuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Low dose oral tolerance is defined as the active suppression of a systemic immune response to a specific antigen by regulatory T cells (Tregs) generated in response to repeated ingestion of that antigen. Though ex- tensively studied, the specific mechanisms involved in the generation of regulatory cells in response to oral antigen remain poorly understood. Although previous studies have demonstrated that oral antigen can in- duce both CD4+ and CD8+ Tregs, the role of CD8+ T cells remains controversial. Our preliminary data dem- onstrate that feeding C57BL/6 mice with the MHC Class' I immunodominant peptide of OVA (SIINFEKL) generates tolerance to subsequent immunization with the whole OVA protein, and that this response is de- pendent on the presence of CD8+ T cells. Our hypothesis is that CD8+ T cells are a major component of the tolerogenic response to oral antigen in a normal immune setting. SIINFEKL binds directly to MHC Class I molecules and therefore stimulates only CD8+ T cells. We propose to harness this to assess the role of CD8+ Tregs in oral tolerance, independently of CD4+ T cells, using an intact immune system. In specific aim 1, we will confirm that SIINFEKL feeding induces the generation of CD8+ Tregs by transfer of tolerance to na- ive mice with CDS" T cells isolated from antigen fed mice, and then localize the sites of antigen uptake and presentation by feeding fluorescent-labeled peptide or protein. In specific aim 2, we will establish the mechanism of how CD8+ Tregs induce suppression, by first establishing whether the mechanism of suppres- sion requires cognate or noncognate interactions using in-vitro suppression assays. We will then identify the mediators involved using flow cytometry by staining SIINFEKL-specific cells with antigen-loaded pentamer, and costaining with antibody against different combinations of phenotypic markers for CD8+ T cell function or regulatory function. Finally, in specific aim 3, we will establish the importance of high affinity interactions be- tween TCR and peptide-MHC complexes in the induction of CD8+ Tregs by feeding peptide variants of SIINFEKL. This is of particular importance as this is the first study to investigate the importance of TCR- antigen affinity in the generation of Tregs in oral tolerance. While numerous studies have demonstrated the therapeutic potential of low dose oral tolerance in the treatment of various animal models of autoimmune disease, several clinical trials have found it to be only marginally successful in the amelioration of disease in humans. The results of these trials have demonstrated that while oral administration of antigen can influ- ence systemic immune responses, there is a need for a more complete understanding of the mechanisms underlying the induction of oral tolerance in order to optimize treatment protocols.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection
-
批准号:10446501
-
项目类别:
-
资助金额:$24.91万
-
财政年份:2022
-
负责人:Paul Michael Arnaboldi
-
依托单位:
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection
-
批准号:10550157
-
项目类别:
-
资助金额:$19.59万
-
财政年份:2022
-
负责人:Paul Michael Arnaboldi
-
依托单位:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
-
批准号:10404209
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2020
-
负责人:Paul Michael Arnaboldi
-
依托单位:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
-
批准号:10452660
-
项目类别:
-
资助金额:$98.65万
-
财政年份:2020
-
负责人:Paul Michael Arnaboldi
-
依托单位:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
-
批准号:10080510
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2020
-
负责人:Paul Michael Arnaboldi
-
依托单位:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
-
批准号:10653862
-
项目类别:
-
资助金额:$97.12万
-
财政年份:2020
-
负责人:Paul Michael Arnaboldi
-
依托单位:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
-
批准号:10668819
-
项目类别:
-
资助金额:$6.54万
-
财政年份:2020
-
负责人:Paul Michael Arnaboldi
-
依托单位:
An antigen-capture assay to screen donated blood for Babesia microti
-
批准号:9893818
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2019
-
负责人:Paul Michael Arnaboldi
-
依托单位:
A Rapid Point-of-Care Assay for the Diagnosis of Lyme Disease
-
批准号:9135755
-
项目类别:
-
资助金额:$15.18万
-
财政年份:2016
-
负责人:Paul Michael Arnaboldi
-
依托单位:
Peptide-based Multiplex Assay for Lyme disease Serodiagnosis
-
批准号:9045060
-
项目类别:
-
资助金额:$17.63万
-
财政年份:2016
-
负责人:Paul Michael Arnaboldi
-
依托单位:
Development of a Cytokine Release Assay as a Diagnostic Test for Lyme Disease
-
批准号:8393091
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Paul Michael Arnaboldi
-
依托单位:
Development of a cytokine release assay for the diagnosis of Lyme disease
-
批准号:9297191
-
项目类别:
-
资助金额:$60.54万
-
财政年份:2012
-
负责人:Paul Michael Arnaboldi
-
依托单位:
Development of a Cytokine Release Assay as a Diagnostic Test for Lyme Disease
-
批准号:8638878
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Paul Michael Arnaboldi
-
依托单位:
海外基金